Leerink’s Geoffrey Porges is pouring cold water over Biogen’s raxatrigine (BIIB074), a neuropathic pain drug it obtained in their $675 million deal to buy Convergence. Writes Porges: “We believe that Biogen’s neuropathic pain treatment candidate raxatrigine (BIIB074) faces long-odds due to the poor record of the class and troubling development history of this molecule; early signals are encouraging but at this stage we don’t see enough consistent evidence of benefit to add this to our model and value proposition for Biogen.”
Former Moderna R&D chief Joseph Bolen has joined Daphne Zohar’s PureTech as its CSO. Bolen, who also had a stint at Millennium, will now take his place at a company that’s routinely scouting for new biotech ideas to advance.
Sweden’s Neurovive has been struggling with Arbutus over the fate a hep B drug dubbed NVP018. But the confrontation is over now. Arbutus is returning its rights to the drug.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,000+ biopharma pros who read Endpoints News by email every day.Free Subscription